Welcome to our dedicated page for Autolus Therapeutics plc SEC filings (Ticker: AUTL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Autolus Therapeutics plc filings document a foreign-issuer ADS structure and material events for a commercial-stage T cell therapy company. The company’s American Depositary Shares trade on the Nasdaq Global Select Market, with each ADS representing one ordinary share, while the ordinary shares are registered in connection with the ADS listing.
Recent Form 8-K disclosures cover financial results, corporate presentations, AUCATZYL revenue updates, pipeline and manufacturing matters, and a master service agreement for lentiviral vector supply used in CAR-T products. The filings also record operational efficiency costs, changes in the company’s independent registered public accounting firm, internal-control disclosures, executive and compensation matters, governance actions and Regulation FD materials.
Autolus Therapeutics plc director Michael W. Bonney received new equity-based compensation. He was granted options to buy 47,500 American Depositary Shares at an exercise price of $1.61 per share, vesting in twelve equal monthly installments starting on July 29, 2026.
He also received 31,667 restricted share units, each representing one American Depositary Share, which vest in a single installment on June 29, 2027. These awards increase his potential future ownership but are subject to time-based vesting.
Autolus Therapeutics plc reported the results of its 2026 Annual General Meeting held on June 29, 2026. Shareholders approved all six ordinary resolutions presented at the meeting.
They received and adopted the 2025 Annual Report and Accounts, with 165,846,326 votes for and 2,895,344 against. The directors’ remuneration report was approved with 156,192,216 votes for and 12,502,946 against. Ernst & Young LLP (US) was appointed as auditors, receiving 165,871,368 votes in favor and 2,872,225 against.
Shareholders also re-elected three directors. Mr. M Bonney was re-elected with 165,491,394 votes for and 3,312,126 against. Dr. E Leiderman was re-elected with 165,741,204 votes for and 3,063,838 against. Mr. R W Azelby was re-elected with 162,133,091 votes for and 6,671,776 against.
Autolus Therapeutics plc has furnished its UK Annual Report and Accounts for the year ended December 31, 2025 and the notice of its annual general meeting, to be held on June 29, 2026, to shareholders. These materials are provided as exhibits and are not incorporated by reference into other securities filings unless expressly stated.
Citibank, as depositary for Autolus’ American Depositary Shares, is mailing voting materials to ADS holders of record as of May 27, 2026 so they can instruct how to vote the underlying ordinary shares. ADS holders are reminded that practical and legal limits may affect the depositary’s ability to execute all instructions.
The UK Annual Report outlines Autolus’ transition to an early commercial-stage biopharmaceutical company, highlighted by US, UK and EU approvals for its CD19 CAR T cell therapy AUCATZYL (obe-cel) in adult relapsed or refractory B‑cell acute lymphoblastic leukaemia and initial launches in the United States and United Kingdom.
Autolus Therapeutics plc ownership update: MAK Capital Fund LP, MAK Capital One L.L.C. and Michael A. Kaufman report beneficial ownership of 33,621,487 ADS (each ADS represents one ordinary share), equal to 12.6% of the outstanding ordinary shares. The percent calculation is based on 266,155,786 ordinary shares outstanding as of May 13, 2026, as reported in the issuer's Form 10-Q. The filing shows shared voting and dispositive power over the 33,621,487 ADS and is signed by Michael A. Kaufman.
Autolus Therapeutics plc received a Schedule 13G/A amendment disclosing that Armistice Capital, LLC and Steven Boyd collectively report beneficial ownership of 15,800,000 American Depositary Shares, representing 5.94% of the ADS class. The filing states Armistice Capital exercises shared voting and dispositive power over those shares under an Investment Management Agreement and is filed as a joint statement dated May 15, 2026.
Autolus Therapeutics plc reports Q1 2026 product revenue of $26.2 million, up from $9.0 million in Q1 2025, driven by AUCATZYL sales in the U.S. and the January 2026 U.K. launch. Despite this growth, the company recorded a net loss of $71.6 million and an operating loss of $59.5 million, with total comprehensive loss of $72.9 million.
Cash, cash equivalents and marketable securities totaled $229.4 million as of March 31, 2026, and management expects these resources to fund operations for at least one year from the statements’ issuance date. Autolus reports liabilities related to future royalties and milestones of $289.2 million, primarily tied to Blackstone and BioNTech funding arrangements.
The company continues to advance obe-cel across additional indications, including lupus nephritis, progressive multiple sclerosis and pediatric B-ALL, and is developing AUTO8 in AL amyloidosis. After quarter end, Autolus approved a restructuring plan, including a workforce reduction of about 13%, targeting annual operating expense savings of approximately $15 million from 2027.
Autolus Therapeutics reported strong commercial momentum for AUCATZYL in the first quarter of 2026, with net product revenue rising to $26.2 million from $9.0 million a year earlier. This shift supported the company’s first positive gross margin for its acute lymphoblastic leukemia business.
Despite this progress, Autolus remains loss-making, with a Q1 2026 net loss of $71.6 million and basic and diluted net loss per share of $(0.27). The company is executing a cost reduction plan, including a workforce reduction of about 13% and expects annualized operating expense savings of roughly $15 million from 2027, after about $8 million in restructuring charges. Management reaffirmed 2026 AUCATZYL net product revenue guidance of $120–$135 million and expects existing cash, cash equivalents and marketable securities of $229.4 million as of March 31, 2026 to fund operations into Q4 2027.
Autolus Therapeutics plc is implementing a restructuring plan that includes a reduction in force affecting approximately 13% of its workforce, leading to estimated total restructuring charges of about $8 million, primarily for severance and related costs. The company expects to record a significant portion of these charges in the first half of 2026 and to substantially complete the workforce reduction by the third quarter of 2026.
Autolus projects that these actions will reduce operating expenses by approximately $15 million on an annualized basis beginning in 2027. It confirmed financial guidance for full-year 2026 AUCATZYL net product revenue of $120 million to $135 million and, based on current plans, continues to expect its cash, cash equivalents and marketable securities to fund operations into the fourth quarter of 2027.